Featured Research

from universities, journals, and other organizations

Diabetes drug target identified

Date:
May 21, 2012
Source:
University of Cincinnati Academic Health Center
Summary:
New research points to the naturally produced protein apolipoprotein A-IV as a potential target for a new diabetes therapeutic.

New research from the University of Cincinnati (UC) points to the naturally produced protein apolipoprotein A-IV (apoA-IV) as a potential target for a new diabetes therapeutic.

Related Articles


Patrick Tso, PhD, professor in the UC Department of Pathology and Laboratory Medicine, has published research on the ability of apoA-IV to reduce blood sugar levels and enhance insulin secretion.

The results appear the week of May 21, 2012, in the online early edition of Proceedings of the National Academy of Sciences.

ApoA-IV is secreted by the small intestine in response to fat absorption. Previous studies have shown apoA-IV to be elevated in humans following gastric bypass -- coinciding with improvement in symptoms for diabetes.

The Tso team found that mice deficient in apoA-IV had impaired glucose tolerance (insulin was not secreted to move glucose from the blood stream). These mice also developed diabetes when continuously fed a high-fat diet. When injected with apoA-IV, these same mice showed improved insulin response to glucose, despite a diet high in fat.

Tso's team also tested the response to injected apoA-IV in diabetic mice and found it reduced glucose levels among that group as well.

Tso says their research shows apoA-IV to behave similar to an incretin -- a gastrointestinal hormone causing an increased release of insulin after eating to combat the onset of elevated blood glucose. Two well-known incretins that have been used in the development of existing diabetes medications include gastric inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP-1).

"The problem with both of these incretins is that they are short-lived -- lasting only for minutes -- and are quickly inactivated by an enzyme," says Tso. "They have also been linked to hypoglycemia, or low blood sugar, when administered when the body has a low glucose concentration. The challenge is to find something safer with a longer half-life."

Tso says apoA-IV has a long half-life (between seven and eight hours) and that tests in his lab showed it to have no effect on glucose levels when administered at low glucose concentrations. Instead, he says, it seems to function to normalize glucose.

The University of Cincinnati has licensed this research finding to a startup biotech company, Apofore Corporation, formed by HealthCare Ventures of Cambridge, Mass. Apofore will further study apoA-IV in humans in an effort to develop a novel diabetes therapeutic.

Tso's research was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.

Co-authors include Sean Davidson, PhD, Tammy Kindel, Alison Kohan, Silvana Obici, PhD, Fei Wang and Stephen Woods, PhD, all from the University of Cincinnati; and Kathryn Corbin and Craig Nunemaker of the University of Virginia, Charlottesville.


Story Source:

The above story is based on materials provided by University of Cincinnati Academic Health Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Fei Wang, Alison B. Kohan, Tammy L. Kindel, Kathryn L. Corbin, Craig S. Nunemaker, Silvana Obici, Stephen C. Woods, W. Sean Davidson, and Patrick Tso. Apolipoprotein A-IV improves glucose homeostasis by enhancing insulin secretion. PNAS, May 22, 2012 DOI: 10.1073/pnas.1201433109

Cite This Page:

University of Cincinnati Academic Health Center. "Diabetes drug target identified." ScienceDaily. ScienceDaily, 21 May 2012. <www.sciencedaily.com/releases/2012/05/120521163847.htm>.
University of Cincinnati Academic Health Center. (2012, May 21). Diabetes drug target identified. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2012/05/120521163847.htm
University of Cincinnati Academic Health Center. "Diabetes drug target identified." ScienceDaily. www.sciencedaily.com/releases/2012/05/120521163847.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins